spacer
home > ebr > winter 2003 > microarrays in the real world
PUBLICATIONS
European Biopharmaceutical Review

Microarrays in the Real World

Since the first microarrays were developed in the early 1990s, the technology for producing and reading has progressed in parallel to the number of applications found for them. The process of using a microarray can be split into four distinct phases; printing, hybridisation, reading and analysis (see Figure 1). As the twin processes of reading the array and analysing the date mediates the quality of the overall experiment, it is essential to understand the issues encountered in these final stages. By referring to the specifics of a two-colour microarray experiment, this article deals with the various practical issues encountered in reading a real chip, many of which are due to relatively simple optical and mechanical effects. The second part of this series will deal with the analysis of the raw image data. Anticipating the issues encountered in the latter two stages leads to both better images and ultimately better results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Julian White, CEO at genapta Ltd

Since completing a PhD in Laser Spectroscopy at Cambridge University, Julian has worked in a number of engineering roles, managing a range of new product designs and introductions over the last decade. For the last five years he has been developing optical sensors for the semiconductor and biotech industries. genapta was founded in 2001 in order to address the potential of transferring techniques widespread in the telecommunications sector to life sciences.

spacer
Julian White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement